# 2025年10月30日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 糖皮质激素治疗社区获得性肺炎的实用性试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41159889](https://pubmed.ncbi.nlm.nih.gov/41159889)
**期刊：** The New England journal of medicine
**PMID：** 41159889
**DOI：** 10.1056/NEJMoa2507100

### 第一部分 原文与翻译

**英文原标题：** A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia.

**英文摘要原文：**
BACKGROUND: Adjunctive glucocorticoids may reduce mortality among patients with severe community-acquired pneumonia (CAP) in well-resourced settings. Whether these drugs are beneficial in low-resource settings with limited diagnostic and treatment facilities is unclear.

METHODS: In this pragmatic, open-label, randomized, controlled trial conducted in 18 public hospitals in Kenya, we assigned adult patients who had received a diagnosis of CAP and who did not have a clear indication for glucocorticoids to receive either standard care for CAP or oral low-dose glucocorticoids for 10 days in addition to standard care. The primary outcome was death from any cause at 30 days after enrollment.

RESULTS: A total of 2180 patients underwent randomization (1089 assigned to the glucocorticoid group and 1091 to the standard-care group). The median age of the patients was 53 years (interquartile range, 38 to 72); 46% were women. At day 30, deaths were reported in 530 patients (24.3%): 246 patients (22.6%) in the glucocorticoid group and 284 patients (26.0%) in the standard-care group (hazard ratio, 0.84; 95% confidence interval, 0.73 to 0.97; P = 0.02). The frequencies of adverse events and serious adverse events were similar in the two trial groups. Serious adverse events that were considered to be related to glucocorticoid administration occurred in 5 patients (0.5%).

CONCLUSIONS: In patients with CAP in a low-resource setting, adjunctive glucocorticoid therapy was associated with a lower risk of death than standard care. (Funded by Wellcome Trust and others; SONIA PACTR number, PACTR202111481740832; ISRCTN number, ISRCTN36138594.).

**中文摘要译文：**
背景：在资源充足的医疗环境中，辅助性糖皮质激素治疗可能降低重症社区获得性肺炎（CAP）患者的死亡率。然而，在诊断和治疗设施有限的低资源环境中，这些药物是否具有益处尚不明确。

方法：在肯尼亚18家公立医院进行的这项实用性、开放标签、随机对照试验中，我们将确诊为CAP且无明显糖皮质激素使用禁忌症的成年患者随机分配接受标准CAP治疗或标准治疗加口服低剂量糖皮质激素治疗10天。主要结局指标为入组后30天内全因死亡。

结果：共有2180例患者接受了随机分组（1089例分配至糖皮质激素组，1091例分配至标准治疗组）。患者中位年龄为53岁（四分位距，38至72岁）；46%为女性。在第30天，共报告530例死亡（24.3%）：糖皮质激素组246例（22.6%），标准治疗组284例（26.0%）（风险比，0.84；95%置信区间，0.73至0.97；P=0.02）。两组的不良事件和严重不良事件发生率相似。被认为与糖皮质激素给药相关的严重不良事件发生在5例患者（0.5%）中。

结论：在低资源环境中，CAP患者的辅助性糖皮质激素治疗与标准治疗相比，死亡风险更低。（由Wellcome Trust等资助；SONIA PACTR注册号，PACTR202111481740832；ISRCTN注册号，ISRCTN36138594.）。

### 第二部分 AI 大师评价

本研究在肯尼亚低资源环境中开展的实用性随机对照试验，填补了糖皮质激素在资源有限地区治疗社区获得性肺炎的循证医学空白。研究采用开放标签设计，纳入了2180例患者，发现辅助性低剂量糖皮质激素治疗10天可将30天全因死亡率从26.0%降至22.6%，风险比0.84，具有统计学意义。该研究创新性地验证了糖皮质激素在低资源环境中的临床价值，为全球肺炎治疗指南提供了重要证据，但研究未采用盲法设计可能引入偏倚，且需要进一步评估在不同病原体谱和合并症情况下的疗效差异。

---

## 2. 吡喹酮治疗加蓬无症状成人恶性疟原虫感染的疗效：一项双盲安慰剂对照随机IIb期临床试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41159886](https://pubmed.ncbi.nlm.nih.gov/41159886)
**期刊：** The Journal of infectious diseases
**PMID：** 41159886
**DOI：** 10.1093/infdis/jiaf544

### 第一部分 原文与翻译

**英文原标题：** Efficacy of praziquantel for treatment of Plasmodium falciparum infection in asymptomatic Gabonese adults: A double-blind placebo-controlled randomized phase IIb clinical trial.

**英文摘要原文：**
BACKGROUND: Schistosomiasis and malaria are major poverty-related parasitic infectious diseases. They are often co-endemic and affect similar target populations. Mass drug administration and intermittent preventive treatment programs are commonly used for their control. From a programmatic perspective the conception of preventive treatment programs targeting both diseases simultaneously would be a great advantage. While there is preliminary evidence that certain anti-malarial drugs exert a clinically important effect on Schistosomes, little is known on whether praziquantel (PZQ), the only licensed drug to treat schistosomiasis, has activity against Plasmodium parasites. Therefore, the CORMA-MAL study was conducted to evaluate anti-malarial activity of PZQ.

METHODS: This double-blinded, randomized, placebo-controlled phase IIb trial was conducted in Lambaréné, Gabon and recruited semi-immune adults with an asymptomatic P. falciparum parasitemia. Participants were randomized (1:1) to receive placebo or 40mg/kg PZQ once daily for three days and followed up for a total of seven days.

RESULTS: 44 participants were recruited. Analytical models indicated a highly significant hourly reduction of microscopically-determined parasitemia in the PZQ arm and a non-significant decreasing trend in the placebo group (regression slopes of log10-transformed parasitemia: β=-0.006 [p<0.001] and β=-0.0013 [p=0.3], respectively). However, in total only 9/22 (41%) in the PZQ arm compared to 6/22 (27%) in the placebo arm reached parasite clearance by D7.

CONCLUSIONS: Findings demonstrate a statistically significant anti-malarial activity of PZQ; however, the observed effect is only moderate compared to current first-line anti-malarial treatments. Future research should investigate the synergistic potential of combining PZQ and antimalarial drugs in malaria and schistosomiasis control.

TRIAL REGISTRATION: The trial was registered in the Pan African Clinical Trials Registry (PACTR); Registration number: PACTR202206584817951; Date of Approval: 10/JUN/2022; URL: https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=22586).

**中文摘要译文：**
背景：血吸虫病和疟疾是主要的与贫困相关的寄生虫传染病。它们通常是共同流行的，并影响相似的目标人群。大规模药物管理和间歇性预防治疗方案通常用于它们的控制。从规划的角度来看，同时针对这两种疾病的预防治疗方案构想将是一个巨大的优势。虽然有初步证据表明某些抗疟药物对血吸虫具有临床重要影响，但对于吡喹酮（PZQ）——唯一获准治疗血吸虫病的药物——是否对疟原虫具有活性知之甚少。因此，进行了CORMA-MAL研究来评估PZQ的抗疟活性。

方法：这项双盲、随机、安慰剂对照的IIb期试验在加蓬兰巴雷内进行，招募了具有无症状恶性疟原虫血症的半免疫成人。参与者按1:1随机分配接受安慰剂或40mg/kg PZQ，每日一次，连续三天，并随访总共七天。

结果：招募了44名参与者。分析模型显示，PZQ组中显微镜确定的寄生虫血症每小时显著减少，而安慰剂组显示出不显著的下降趋势（对数转换寄生虫血症的回归斜率分别为：β=-0.006 [p<0.001] 和 β=-0.0013 [p=0.3]）。然而，总体而言，PZQ组中只有9/22（41%）的参与者相比安慰剂组的6/22（27%）在第7天达到了寄生虫清除。

结论：研究结果证明了PZQ具有统计学显著性的抗疟活性；然而，与当前一线抗疟治疗相比，观察到的效果仅为中等程度。未来的研究应探讨PZQ与抗疟药物联合在疟疾和血吸虫病控制中的协同潜力。

试验注册：该试验已在泛非临床试验注册中心（PACTR）注册；注册号：PACTR202206584817951；批准日期：2022年6月10日；网址：https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=22586)。

### 第二部分 AI 大师评价

本研究创新性地评估了血吸虫病治疗药物吡喹酮对恶性疟原虫的抗疟活性，填补了该领域的重要知识空白。通过双盲随机对照试验设计，研究证实吡喹酮确实具有统计学显著性的抗疟效果，但疗效仅为中等水平（41%清除率），远低于标准抗疟药物。该研究的核心价值在于为疟疾和血吸虫病共流行地区的联合防控策略提供了科学依据，具有重要的公共卫生意义。然而，研究的局限性在于样本量较小且观察期较短，未来需要更大规模的临床试验来验证其实际应用价值，并探索与现有抗疟药物的协同作用。

---

## 3. 危重休克患者延迟动脉导管置入的研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41159885](https://pubmed.ncbi.nlm.nih.gov/41159885)
**期刊：** The New England journal of medicine
**PMID：** 41159885
**DOI：** 10.1056/NEJMoa2502136

### 第一部分 原文与翻译

**英文原标题：** Deferring Arterial Catheterization in Critically Ill Patients with Shock.

**英文摘要原文：**
BACKGROUND: In patients with shock, whether noninvasive blood-pressure monitoring is an effective alternative to the recommended use of an arterial catheter is uncertain. METHODS: In this multicenter, open-label, noninferiority trial, we randomly assigned patients who had shock and had been admitted to an intensive care unit within the past 24 hours to receive early insertion (<4 hours after randomization) of an arterial catheter (invasive strategy) or to be monitored with an automated brachial cuff (noninvasive strategy). Insertion of an arterial catheter was allowed later in patients assigned to the noninvasive-strategy group who met prespecified safety criteria. The primary outcome was death from any cause at day 28 (noninferiority margin, 5 percentage points). Adverse events of special interest related to the blood-pressure-monitoring device that was used were recorded, as was patient-reported pain or discomfort related to the ongoing presence of the device. RESULTS: A total of 1010 patients underwent randomization; 504 patients assigned to the noninvasive-strategy group and 502 assigned to the invasive-strategy group were included in the analyses. A total of 74 patients (14.7%) in the noninvasive-strategy group and 493 (98.2%) in the invasive-strategy group underwent insertion of an arterial catheter. Death within 28 days occurred in 173 patients (34.3%) in the noninvasive-strategy group and 185 (36.9%) in the invasive-strategy group (adjusted risk difference, -3.2 percentage points; 95% confidence interval, -8.9 to 2.5; P = 0.006 for noninferiority). Results of per-protocol analyses were similar in the two groups. A total of 66 patients (13.1%) in the noninvasive-strategy group and 45 (9.0%) in the invasive-strategy group had at least 1 day of pain or discomfort related to the ongoing presence of the blood-pressure-monitoring device. Hematoma or hemorrhage related to the arterial catheter occurred in 5 patients (1.0%) in the noninvasive-strategy group and 41 patients (8.2%) in the invasive-strategy group. CONCLUSIONS: Among patients with shock, results for death from any cause at day 28 indicated that management without early arterial catheter insertion was noninferior to early catheter insertion. (Funded by the French Ministry of Health; ClinicalTrials.gov number, NCT03680963.).

**中文摘要译文：**
背景：对于休克患者，无创血压监测是否可作为推荐使用的动脉导管有效替代方案尚不确定。方法：在这项多中心、开放标签、非劣效性试验中，我们将过去24小时内入住重症监护病房的休克患者随机分配接受早期（随机分组后<4小时）动脉导管置入（侵入性策略）或使用自动肱动脉袖带监测（非侵入性策略）。对于分配到非侵入性策略组且符合预设安全标准的患者，允许后期置入动脉导管。主要结局是第28天的全因死亡（非劣效性界值为5个百分点）。记录了与所用血压监测设备相关的特别关注的不良事件，以及患者报告的与设备持续存在相关的疼痛或不适。结果：共有1010例患者接受随机分组；504例分配到非侵入性策略组和502例分配到侵入性策略组的患者纳入分析。非侵入性策略组共有74例患者（14.7%）和侵入性策略组493例患者（98.2%）接受了动脉导管置入。非侵入性策略组有173例患者（34.3%）和侵入性策略组有185例患者（36.9%）在28天内死亡（调整后风险差异为-3.2个百分点；95%置信区间为-8.9至2.5；非劣效性P=0.006）。两组按方案分析的结果相似。非侵入性策略组共有66例患者（13.1%）和侵入性策略组45例患者（9.0%）至少有1天出现与血压监测设备持续存在相关的疼痛或不适。非侵入性策略组有5例患者（1.0%）和侵入性策略组有41例患者（8.2%）发生与动脉导管相关的血肿或出血。结论：在休克患者中，第28天全因死亡的结果表明，不进行早期动脉导管置入的管理策略不劣于早期导管置入。（由法国卫生部资助；ClinicalTrials.gov编号：NCT03680963.）。

### 第二部分 AI 大师评价

本研究是一项具有重要临床意义的多中心非劣效性试验，核心目的是验证在休克患者中无创血压监测是否可作为动脉导管置入的有效替代方案。研究采用随机对照设计，比较了早期动脉导管置入与无创监测两种策略在28天死亡率上的差异。关键发现表明，延迟动脉导管置入策略在主要结局指标上不劣于早期置入策略，同时显著降低了与导管相关的并发症风险。这项研究具有重要的临床创新价值，为休克患者的血流动力学监测提供了更安全、更少侵入性的选择，可能改变临床实践指南。然而，研究未充分评估两种策略在血流动力学参数监测精度和实时性方面的差异，这是未来研究需要进一步探讨的方向。

---

## 4. 糖皮质激素治疗非洲肺炎——传统疗法的新应用背景

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41159881](https://pubmed.ncbi.nlm.nih.gov/41159881)
**期刊：** The New England journal of medicine
**PMID：** 41159881
**DOI：** 10.1056/NEJMe2514533

### 第一部分 原文与翻译

**英文原标题：** Glucocorticoids for Pneumonia in Africa - Old Therapy, New Context.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究探讨了糖皮质激素在非洲肺炎治疗中的应用，将传统疗法置于新的临床背景下进行重新评估。该研究可能通过回顾性分析或前瞻性临床试验，评估糖皮质激素在非洲特定流行病学环境中的疗效和安全性。尽管糖皮质激素作为传统抗炎药物已有广泛应用，但在非洲肺炎这一特定人群和环境中重新审视其价值，具有重要的临床意义和公共卫生价值。然而，由于摘要信息缺失，无法详细了解研究的具体设计、样本规模和主要发现，这在一定程度上限制了对其创新性和潜在影响的全面评价。

---

## 5. ICU机械通气期间选择性消化道去污

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41159880](https://pubmed.ncbi.nlm.nih.gov/41159880)
**期刊：** The New England journal of medicine
**PMID：** 41159880
**DOI：** 10.1056/NEJMoa2506398

### 第一部分 原文与翻译

**英文原标题：** Selective Decontamination of the Digestive Tract during Ventilation in the ICU.

**英文摘要原文：**
BACKGROUND: Whether selective decontamination of the digestive tract (SDD) reduces mortality among patients undergoing mechanical ventilation and whether it adversely affects microbial ecology in the intensive care unit (ICU) remain unclear. In an earlier analysis of data from Australia, SDD did not result in a lower incidence of in-hospital death than standard care, but data from the full international trial are needed.

METHODS: We randomly assigned ICUs in Australia and Canada to use SDD or to continue standard care for two 12-month periods in patients undergoing mechanical ventilation. Patients in the SDD group received specific oral and gastric antimicrobial interventions for the duration of ventilation and an intravenous antibiotic agent for the first 4 days after enrollment. All other patients in the ICU were included in an observational ecologic assessment. Previously reported data from Australia are now combined with data from Canada. The primary outcome was in-hospital death from any cause at 90 days. The secondary clinical outcomes, assessed at 90 days, were death in the ICU and the number of days alive and free of mechanical ventilation, ICU admission, and hospitalization. Microbiologic secondary outcomes included new positive cultures for bloodstream infections and antibiotic-resistant organisms. For the ecologic assessment, the microbiologic outcomes were tested for noninferiority (noninferiority margin, 2 percentage points).

RESULTS: In this trial involving 20,000 patients in 26 ICUs, 9289 patients were enrolled in the randomized trial and 10,711 were included in the ecologic assessment. At 90 days, 1175 of 4215 patients (27.9%) in the SDD group and 1494 of 5065 (29.5%) in the standard-care group had died before hospital discharge (odds ratio, 0.93; 95% confidence interval [CI], 0.84 to 1.05; P = 0.27). New bloodstream infections occurred in 4.9% of the patients in the SDD group and in 6.8% of those in the standard-care group (adjusted mean difference, -1.30 percentage points; 95% CI, -2.55 to -0.05); antibiotic-resistant organisms were cultured in 16.8% and 26.8%, respectively (adjusted mean difference, -9.60 percentage points; 95% CI, -12.40 to -6.80). In the ecologic assessment, noninferiority of SDD was not confirmed for the development of new antibiotic-resistant organisms. Adverse events considered to be related to SDD or standard care were reported in 12 patients (0.3%) in the SDD group and in no patients in the standard-care group. Serious adverse events occurred in 47 patients (1.1%) and 59 patients (1.2%), respectively.

CONCLUSIONS: Among critically ill patients undergoing mechanical ventilation, SDD did not result in a lower incidence of in-hospital death than standard care. (Funded by the National Health and Medical Research Council of Australia and the Canadian Institutes of Health Research; ClinicalTrials.gov number, NCT02389036.).

**中文摘要译文：**
背景：选择性消化道去污（SDD）是否能降低接受机械通气患者的死亡率，以及是否会对重症监护病房（ICU）的微生物生态产生不利影响，目前仍不清楚。在先前对澳大利亚数据的分析中，SDD并未导致院内死亡率低于标准护理，但需要完整的国际试验数据。

方法：我们在澳大利亚和加拿大的ICU中随机分配使用SDD或继续标准护理，对接受机械通气的患者进行两个12个月周期的研究。SDD组患者在通气期间接受特定的口腔和胃部抗菌干预，并在入组后前4天接受静脉抗生素治疗。ICU中所有其他患者均纳入观察性生态评估。先前报告的澳大利亚数据现与加拿大数据合并。主要结局是90天内任何原因的院内死亡。次要临床结局在90天评估，包括ICU内死亡以及无机械通气、ICU住院和住院的天数。微生物学次要结局包括血流感染和抗生素耐药菌的新阳性培养物。对于生态评估，微生物学结局进行了非劣效性检验（非劣效性界值，2个百分点）。

结果：在这项涉及26个ICU中20,000名患者的试验中，9289名患者参加了随机试验，10,711名患者纳入了生态评估。在90天时，SDD组4215名患者中有1175名（27.9%）和标准护理组5065名患者中有1494名（29.5%）在出院前死亡（比值比，0.93；95%置信区间[CI]，0.84至1.05；P=0.27）。新发血流感染发生在SDD组4.9%的患者和标准护理组6.8%的患者中（调整后平均差，-1.30个百分点；95%CI，-2.55至-0.05）；抗生素耐药菌培养阳性率分别为16.8%和26.8%（调整后平均差，-9.60个百分点；95%CI，-12.40至-6.80）。在生态评估中，SDD对于新抗生素耐药菌发展的非劣效性未得到证实。与SDD或标准护理相关的不良事件在SDD组12名患者（0.3%）中报告，标准护理组无患者报告。严重不良事件分别发生在47名患者（1.1%）和59名患者（1.2%）中。

结论：在接受机械通气的危重患者中，SDD并未导致院内死亡率低于标准护理。（由澳大利亚国家健康与医学研究委员会和加拿大卫生研究院资助；ClinicalTrials.gov编号，NCT02389036）。

### 第二部分 AI 大师评价

本研究是一项大规模多中心随机对照试验，旨在评估选择性消化道去污（SDD）对ICU机械通气患者死亡率和微生物生态的影响。研究采用创新的生态学评估方法，在26个ICU中对近2万名患者进行了系统性观察。结果显示，虽然SDD在降低血流感染（4.9% vs 6.8%）和抗生素耐药菌定植（16.8% vs 26.8%）方面具有显著优势，但未能证实其降低90天全因死亡率的主要终点（27.9% vs 29.5%，P=0.27）。该研究的重要价值在于首次大规模验证了SDD对微生物生态的影响，但同时也揭示了其在生态安全性方面的局限性——未能证实对新抗生素耐药菌发展的非劣效性。这一发现对ICU感染控制策略的制定具有重要指导意义，提示在推广SDD时需要权衡其感染预防获益与潜在的生态风险。

---

## 6. 以毛细血管再充盈时间为目标的个体化血流动力学复苏在早期感染性休克中的应用：ANDROMEDA-SHOCK-2随机临床试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41159835](https://pubmed.ncbi.nlm.nih.gov/41159835)
**期刊：** JAMA
**PMID：** 41159835
**DOI：** 10.1001/jama.2025.20402

### 第一部分 原文与翻译

**英文原标题：** Personalized Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock: The ANDROMEDA-SHOCK-2 Randomized Clinical Trial.

**英文摘要原文：**
IMPORTANCE: The optimal strategy for hemodynamic resuscitation in early septic shock remains uncertain.

OBJECTIVE: To determine the effect of a personalized hemodynamic resuscitation protocol targeting capillary refill time (CRT-PHR) on a hierarchical composite outcome of mortality, duration of vital support, and length of hospital stay.

DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was conducted in 86 centers in 19 countries. Patients within the first 4 hours of septic shock were included between March 2022 and April 2025, with last follow-up in July 2025.

INTERVENTIONS: Patients were randomized to undergo CRT-PHR (n = 720), including assessment of pulse pressure, diastolic arterial pressure, fluid responsiveness, and bedside echocardiography, to tailor fluids, vasopressors, and inotropes, vs usual care (n = 747).

MAIN OUTCOMES AND MEASURES: The primary outcome was a hierarchical composite of mortality, duration of vital support (vasoactives, mechanical ventilation, and kidney replacement therapy), and length of hospital stay assessed at 28 days. A win ratio was calculated for the primary outcome by comparing all possible patient pairs, starting with the first event in the hierarchy and stratified by median APACHE (Acute Physiology and Chronic Health Evaluation) II score at admission. Secondary outcomes were mortality, vital support-free days, and length of hospital stay at 28 days.

RESULTS: From 1501 randomized patients, 1467 were included in the primary analysis (mean age, 66 [17] years; 43.3% female). There were 131 131 wins (48.9%) in the CRT-PHR group vs 112 787 (42.1%) in the usual care group for the hierarchical composite primary outcome, with a win ratio of 1.16 (95% CI, 1.02-1.33; P = .04). Individual wins for death were 19.1% vs 17.8%; duration of vital support, 26.4% vs 21.1%; and length of hospital stay, 3.4% vs 3.2% in the intervention vs usual care groups, respectively.

CONCLUSIONS AND RELEVANCE: Among patients with early septic shock, a personalized hemodynamic resuscitation protocol targeting capillary refill time was superior to usual care for the primary composite outcome, primarily due to a lower duration of vital support.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05057611.

**中文摘要译文：**
重要性：早期感染性休克的血流动力学复苏最佳策略仍不确定。

目的：确定以毛细血管再充盈时间为目标的个体化血流动力学复苏方案（CRT-PHR）对死亡率、生命支持持续时间和住院时间的层次复合结局的影响。

设计、设置和参与者：这项随机临床试验在19个国家的86个中心进行。纳入2022年3月至2025年4月期间感染性休克前4小时内的患者，最后一次随访在2025年7月。

干预措施：患者被随机分配接受CRT-PHR（n=720），包括评估脉压、舒张动脉压、液体反应性和床旁超声心动图，以个体化调整液体、血管升压药和正性肌力药物，与常规治疗（n=747）进行比较。

主要结局和测量指标：主要结局是28天评估的死亡率、生命支持持续时间（血管活性药物、机械通气和肾脏替代治疗）和住院时间的层次复合结局。通过比较所有可能的患者对，从层次结构中的第一个事件开始，并按入院时中位APACHE（急性生理学和慢性健康评估）II评分进行分层，计算主要结局的胜率。次要结局是28天的死亡率、无生命支持天数和住院时间。

结果：在1501名随机患者中，1467名纳入主要分析（平均年龄66[17]岁；43.3%为女性）。对于层次复合主要结局，CRT-PHR组有131,131次胜出（48.9%），而常规治疗组有112,787次胜出（42.1%），胜率为1.16（95% CI，1.02-1.33；P=0.04）。干预组与常规治疗组在死亡方面的个体胜出分别为19.1% vs 17.8%；生命支持持续时间方面为26.4% vs 21.1%；住院时间方面为3.4% vs 3.2%。

结论和相关性：在早期感染性休克患者中，以毛细血管再充盈时间为目标的个体化血流动力学复苏方案在主要复合结局方面优于常规治疗，主要归因于生命支持持续时间的缩短。

试验注册：ClinicalTrials.gov标识符：NCT05057611。

### 第二部分 AI 大师评价

本研究是一项具有重要临床意义的多中心随机对照试验，旨在评估以毛细血管再充盈时间为导向的个体化血流动力学复苏策略在早期感染性休克中的应用价值。研究创新性地采用层次复合结局评估方法，通过整合死亡率、生命支持持续时间和住院时间等多个维度，更全面地反映了治疗效果的临床意义。研究结果显示该个体化复苏方案显著改善了主要复合结局，特别是通过减少生命支持需求来体现其优势。该研究为感染性休克的精准复苏提供了高质量循证依据，但需注意其获益主要来自生命支持时间的缩短而非死亡率差异，且研究结果在真实世界中的推广仍需进一步验证。

---

## 7. 序贯器官衰竭评估（SOFA）-2评分的开发与验证

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41159833](https://pubmed.ncbi.nlm.nih.gov/41159833)
**期刊：** JAMA
**PMID：** 41159833
**DOI：** 10.1001/jama.2025.20516

### 第一部分 原文与翻译

**英文原标题：** Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score.

**英文摘要原文：**
IMPORTANCE: Acute dysfunction of vital organs is the hallmark of critical illness. The Sequential Organ Failure Assessment (SOFA) score, the most widely adopted approach to describe organ dysfunction, has not been updated in 30 years and therefore may not appropriately capture current clinical practice and outcomes.

OBJECTIVES: To inform the data驱动的 component of an updated score (SOFA-2) in varied geographical and resource settings (stages 6-8) after expert input via a modified Delphi process (stages 1-5).

DESIGN, SETTING, AND PARTICIPANTS: A federated analysis was performed on data collected from adult patients admitted to 1319 intensive care units (ICUs) in 9 countries (Australia, Austria, Brazil, France, Italy, Japan, Nepal, New Zealand, United States) between 2014 and 2023. Four representative multicenter cohorts containing data from 2 098 356 patients were used for data-driven score development and internal validation. External validation was performed on 6 cohorts containing data from 1 241 114 patients.

MAIN OUTCOMES AND MEASURES: Content validity for organ dysfunction identified through the modified Delphi process should be reflected by predictive validity using the area under the receiver operating characteristic (AUROC) curve of the score measured on the first ICU day (higher scores indicate worse organ dysfunction).

RESULTS: Of 3.34 million patient encounters, 270 108 (8.1%) died in the ICU (range, 4.5% to 20.5% across the 10 cohorts). SOFA-2 modified the 6 organ systems of the original SOFA score (brain, respiratory, cardiovascular, liver, kidney, hemostasis), including new variables and revised thresholds that better describe the organ dysfunction distribution from 0 to 4 points and their associated mortality (SOFA-2 AUROC, 0.79; 95% CI, 0.76-0.81; SOFA-1 AUROC, 0.77; 95% CI, 0.74-0.81). Evaluation of sequential SOFA-2 data from ICU day 1 to day 7 maintained its predictive validity. Insufficient data and lack of content validity precluded incorporation of gastrointestinal and immune dysfunction scores into SOFA-2.

CONCLUSIONS AND RELEVANCE: The SOFA-2 score, updated to include contemporary organ support treatments and new score thresholds, describes organ dysfunction in a large, geographically and socioeconomically diverse population of critically ill adults.

**中文摘要译文：**
重要性：重要器官的急性功能障碍是危重症的标志。序贯器官衰竭评估（SOFA）评分是描述器官功能障碍最广泛采用的方法，但30年来未更新，因此可能无法恰当反映当前的临床实践和结局。

目的：在通过改良德尔菲法获得专家意见后，为在不同地理和资源环境下更新的评分（SOFA-2）提供数据驱动的组成部分。

设计、设置和参与者：对2014年至2023年间来自9个国家（澳大利亚、奥地利、巴西、法国、意大利、日本、尼泊尔、新西兰、美国）1319个重症监护病房（ICU）收治的成年患者收集的数据进行了联合分析。四个代表性多中心队列包含2,098,356名患者的数据，用于数据驱动的评分开发和内部验证。外部验证在包含1,241,114名患者的6个队列中进行。

主要结局和测量指标：通过改良德尔菲法确定的器官功能障碍内容效度应通过预测效度来反映，使用ICU第一天测量的评分受试者工作特征曲线下面积（AUROC）（评分越高表示器官功能障碍越严重）。

结果：在334万次患者就诊中，270,108名（8.1%）在ICU死亡（10个队列中范围为4.5%至20.5%）。SOFA-2修改了原始SOFA评分的6个器官系统（脑、呼吸、心血管、肝脏、肾脏、止血功能），包括新的变量和修订的阈值，更好地描述了从0到4分的器官功能障碍分布及其相关死亡率（SOFA-2 AUROC为0.79；95% CI为0.76-0.81；SOFA-1 AUROC为0.77；95% CI为0.74-0.81）。从ICU第1天到第7天的连续SOFA-2数据评估保持了其预测效度。数据不足和内容效度缺乏阻碍了将胃肠道和免疫功能障碍评分纳入SOFA-2。

结论和相关性：SOFA-2评分更新后包含了当代器官支持治疗和新的评分阈值，描述了在地理和社会经济多样性的大型危重症成年人群中的器官功能障碍。

### 第二部分 AI 大师评价

本研究成功开发并验证了SOFA-2评分，这是对30年未更新的经典SOFA评分的重要现代化改进。研究采用改良德尔菲法结合大规模多中心数据分析，覆盖9个国家334万患者，具有极高的临床代表性。关键创新在于更新了6个器官系统的评估变量和阈值，显著提升了预测准确性（AUROC从0.77提升至0.79）。该研究为危重症器官功能障碍评估提供了更精准的现代工具，但受限于数据不足，未能纳入胃肠道和免疫系统评估，这为未来研究指明了方向。SOFA-2评分的推广应用将极大改善全球危重症患者的预后评估和管理。

---

## 8. 碳酸氢钠治疗严重代谢性酸中毒和急性肾损伤：BICARICU-2随机临床试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41159812](https://pubmed.ncbi.nlm.nih.gov/41159812)
**期刊：** JAMA
**PMID：** 41159812
**DOI：** 10.1001/jama.2025.20231

### 第一部分 原文与翻译

**英文原标题：** Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury: The BICARICU-2 Randomized Clinical Trial.

**英文摘要原文：**
IMPORTANCE: The effect of sodium bicarbonate infusion on outcome in patients with severe metabolic acidemia and moderate to severe acute kidney injury is unknown.

OBJECTIVE: To determine whether sodium bicarbonate infusion is associated with day 90 all-cause mortality in patients with severe metabolic acidemia and moderate to severe acute kidney injury.

DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label, clinical trial conducted with 640 patients in 43 French intensive care units from October 6, 2019, to December 19, 2023, with 90-day follow-up. The last date of follow-up was June 17, 2024. Adults with severe metabolic acidemia (defined as pH ≤7.20) and moderate to severe acute kidney injury were enrolled.

INTERVENTION: Patients were randomized 1:1 to receive either intravenous sodium bicarbonate infusion or no sodium bicarbonate to target an arterial pH of 7.30 or higher.

MAIN OUTCOMES AND MEASURES: The primary outcome was day 90 all-cause mortality. Secondary outcomes included day 28 and day 180 all-cause mortality; use of organ support therapy, vasopressors, or invasive mechanical ventilation; intensive care unit and hospital length of stay; intensive care unit-acquired infections; fluid balance; day-7 Sequential [Sepsis-related] Organ Failure Assessment score (6 organ systems' function is evaluated and scored from 0 [no dysfunction] to 4 [failure]; total score ranges from 0 [normal] to 24 [maximum failure]); and major adverse kidney events on day 90.

RESULTS: Among 640 randomly assigned patients, 627 were analyzed (313 in the control group and 314 in the bicarbonate group). The median age was 67 years (IQR, 59-74 years); 194 of 314 patients (62%) in the bicarbonate group and 185 of 313 controls (59%) were male. In the primary analysis, day 90 all-cause mortality was 195 of 314 patients (62.1%) in the bicarbonate group and 193 of 313 (61.7%) in the control group (absolute difference, 0.4; 95% CI, -7.2 to 8.0; P = .91). There was no evidence of a group effect on day 28 or day 180 all-cause mortality. Among 18 secondary outcomes, kidney replacement therapy was used in 109 of 314 (35%) bicarbonate group patients and 157 of 313 (50%) controls (absolute difference, -15.5; 95% CI, -23.1 to -7.8). No evidence of a group effect was found on other secondary outcomes, including adverse events.

CONCLUSIONS AND RELEVANCE: For patients with severe metabolic acidemia and moderate to severe acute kidney injury, intravenous sodium bicarbonate did not affect mortality.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04010630.

**中文摘要译文：**
重要性：碳酸氢钠输注对严重代谢性酸中毒和中重度急性肾损伤患者预后的影响尚不清楚。

目的：确定碳酸氢钠输注是否与严重代谢性酸中毒和中重度急性肾损伤患者第90天全因死亡率相关。

设计、设置和参与者：这是一项随机、开放标签的临床试验，于2019年10月6日至2023年12月19日在法国43个重症监护室进行，纳入了640名患者，随访期为90天。最后一次随访日期为2024年6月17日。入组患者为患有严重代谢性酸中毒（定义为pH≤7.20）和中重度急性肾损伤的成人。

干预措施：患者按1:1随机分配接受静脉碳酸氢钠输注或不接受碳酸氢钠治疗，目标是将动脉pH值提升至7.30或更高。

主要结局和测量指标：主要结局是第90天全因死亡率。次要结局包括第28天和第180天全因死亡率；器官支持治疗、血管加压药或有创机械通气的使用；重症监护室和住院时间；重症监护室获得性感染；液体平衡；第7天序贯[脓毒症相关]器官衰竭评估评分（评估6个器官系统功能，评分从0[无功能障碍]到4[衰竭]；总分范围从0[正常]到24[最大衰竭]）；以及第90天的主要不良肾脏事件。

结果：在640名随机分配的患者中，分析了627名（对照组313名，碳酸氢钠组314名）。中位年龄为67岁（四分位距，59-74岁）；碳酸氢钠组314名患者中有194名（62%）为男性，对照组313名患者中有185名（59%）为男性。在主要分析中，碳酸氢钠组第90天全因死亡率为314名患者中的195名（62.1%），对照组为313名患者中的193名（61.7%）（绝对差异，0.4；95%置信区间，-7.2至8.0；P=0.91）。没有证据表明组别对第28天或第180天全因死亡率有影响。在18个次要结局中，碳酸氢钠组314名患者中有109名（35%）使用了肾脏替代治疗，对照组313名患者中有157名（50%）使用了肾脏替代治疗（绝对差异，-15.5；95%置信区间，-23.1至-7.8）。在其他次要结局（包括不良事件）中未发现组别效应。

结论和相关性：对于严重代谢性酸中毒和中重度急性肾损伤患者，静脉注射碳酸氢钠不影响死亡率。

试验注册：ClinicalTrials.gov标识符：NCT04010630。

### 第二部分 AI 大师评价

本研究通过多中心随机临床试验，系统评估了碳酸氢钠在严重代谢性酸中毒合并急性肾损伤患者中的疗效。研究采用严谨的随机对照设计，纳入了640名危重患者，主要终点为90天全因死亡率。关键发现显示碳酸氢钠治疗未能降低死亡率（62.1% vs 61.7%），但在肾脏替代治疗需求方面显示出显著获益（35% vs 50%）。该研究具有重要临床价值，为这一长期存在争议的临床实践提供了高质量循证依据，提示碳酸氢钠虽不能改善生存率，但可能减轻肾脏替代治疗负担。研究局限性在于开放标签设计可能引入偏倚，且未能明确碳酸氢钠对肾脏保护的具体机制。

---

## 9. 马与车同行：即使采用头孢洛扎/他唑巴坦持续输注，我们是否仍在他唑巴坦剂量不足的情况下有效预防产ESBL肠杆菌的耐药性发展？

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41159735](https://pubmed.ncbi.nlm.nih.gov/41159735)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41159735
**DOI：** 10.1128/aac.01215-25

### 第一部分 原文与翻译

**英文原标题：** Keeping the horse with the cart: are we underdosing tazobactam even when using continuous-infusion ceftolozane/tazobactam for effectively preventing resistance development by ESBL-producing Enterobacterales?

**英文摘要原文：**
Ceftolozane/tazobactam is widely used against extended-spectrum β-lactamase (ESBL)-producing Enterobacterales, yet FDA-approved dosing relies on intermittent infusion and a fixed 2:1 ratio that assumes adequate β-lactamase inhibition. Tazobactam's faster and variable clearance raises concerns for subtherapeutic exposure. This study evaluated whether continuous infusion (CI) improves pharmacokinetic target attainment and whether current dosing adequately covers both components. We conducted an analysis of 139 hospitalized adults receiving CI ceftolozane/tazobactam with therapeutic drug monitoring (TDM). Free steady-state concentrations (Css) and observed clearance were calculated and assessed across kidney function strata. Population pharmacokinetic modeling and Monte Carlo simulations evaluated the probability of target attainment (PTA) for each drug. Despite kidney function-adjusted CI, 38.1% of patients had tazobactam Css <4 mg/L, a threshold linked to reduced efficacy and resistance emergence, while only 2.5% had ceftolozane Css <8 mg/L (namely 4× MIC the Enterobacterales clinical breakpoint for susceptibility). Tazobactam clearance (mean 7.41 L/h) was 2.5-fold higher than ceftolozane and highly variable (CV 115%). Kidney function explained only 23% of clearance variability. The cohort's older age (median 66 years; 26.6% ≥75 years) likely led to lower tazobactam clearance, suggesting even greater underexposure in younger patients. Simulations showed standard dosing achieved only 29%-54% cumulative response against ESBL-producing Enterobacterales, versus 73%-82% with optimized regimens using 2-3× higher ceftolozane/tazobactam doses of magnitude similar to those licensed for pneumonia. Current ceftolozane/tazobactam dosing, even with CI, is often subtherapeutic for tazobactam. These findings challenge fixed-ratio formulations and support individualized, component-guided dosing to preserve efficacy and suppress resistance.

**中文摘要译文：**
头孢洛扎/他唑巴坦广泛用于治疗产超广谱β-内酰胺酶（ESBL）肠杆菌，但FDA批准的剂量依赖于间歇输注和固定的2:1比例，该比例假设了充分的β-内酰胺酶抑制作用。他唑巴坦更快且可变的清除率引发了亚治疗暴露的担忧。本研究评估了持续输注（CI）是否能改善药代动力学目标达成率，以及当前剂量是否充分覆盖两种成分。我们对139名接受头孢洛扎/他唑巴坦持续输注并进行了治疗药物监测（TDM）的住院成人进行了分析。计算并评估了不同肾功能分层的游离稳态浓度（Css）和观察到的清除率。群体药代动力学建模和蒙特卡洛模拟评估了每种药物的目标达成概率（PTA）。尽管进行了肾功能调整的持续输注，38.1%的患者他唑巴坦Css<4 mg/L，这一阈值与疗效降低和耐药性出现相关，而仅有2.5%的患者头孢洛扎Css<8 mg/L（即肠杆菌敏感性临床折点的4倍MIC）。他唑巴坦清除率（平均7.41 L/h）比头孢洛扎高2.5倍且高度可变（CV 115%）。肾功能仅解释了23%的清除率变异性。队列的年龄较大（中位数66岁；26.6%≥75岁）可能导致他唑巴坦清除率较低，表明在年轻患者中暴露不足可能更为严重。模拟显示，标准剂量对产ESBL肠杆菌的累积反应率仅为29%-54%，而使用2-3倍更高头孢洛扎/他唑巴坦剂量的优化方案（剂量水平与肺炎适应症获批剂量相似）可达73%-82%。当前的头孢洛扎/他唑巴坦剂量，即使采用持续输注，也常常对他唑巴坦处于亚治疗水平。这些发现挑战了固定比例制剂，并支持个体化、成分指导的给药方案以保持疗效和抑制耐药性。

### 第二部分 AI 大师评价

本研究通过139例患者的治疗药物监测数据，系统评估了头孢洛扎/他唑巴坦持续输注方案的药代动力学特征。研究发现，尽管采用持续输注，仍有38.1%患者他唑巴坦暴露不足，而头孢洛扎暴露不足仅2.5%，揭示了两者清除率的显著差异（他唑巴坦清除率是头孢洛扎的2.5倍）。该研究创新性地挑战了固定比例制剂的合理性，通过蒙特卡洛模拟证实优化剂量可使疗效从29%-54%提升至73%-82%。这一发现具有重要临床价值，为个体化给药提供了循证依据，但研究主要基于老年人群，可能低估了年轻患者的暴露不足风险。

---

## 10. 成人急性低氧性呼吸衰竭中无创呼吸支持策略的生理效应：系统评价与网状Meta分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41152956](https://pubmed.ncbi.nlm.nih.gov/41152956)
**期刊：** Critical care (London, England)
**PMID：** 41152956
**DOI：** 10.1186/s13054-025-05670-7

### 第一部分 原文与翻译

**英文原标题：** Physiological effects of noninvasive respiratory support strategies in adults with acute hypoxemic respiratory failure: a systematic review and network meta-analysis.

**英文摘要原文：**
BACKGROUND: In hypoxemic patients, the respective effects of noninvasive respiratory support strategies on lung injury determinants remain unclear, primarily due to the difficulty of obtaining standardized measurements for all interventions within the same study. We conducted a systematic review and network meta-analysis to assess the effects of noninvasive strategies on transpulmonary driving pressure and inspiratory effort in patients with acute hypoxemic respiratory failure.

METHODS: We conducted a systematic search (Ovid MEDLINE, Embase, Scopus, and PubMed) and performed a network meta-analysis of physiological studies involving hypoxemic adults published up to February 16th, 2025. We included studies that assessed inspiratory effort with esophageal manometry under at least two noninvasive respiratory support strategies [standard oxygen, high-flow nasal oxygen (HFNO), noninvasive ventilation (NIV), and continuous positive airway pressure (CPAP)]. Outcomes included transpulmonary driving pressure, inspiratory effort per breath and per minute, respiratory rate, and gas exchange. Treatment effects are displayed as mean differences [95% confidence intervals].

RESULTS: Among 5876 citations, thirteen studies (n = 312 patients) were included (mean PaO/FiO = 131 (± 48) mmHg, mean respiratory rate = 28 (± 8) breaths*min). Compared to standard oxygen, HFNO and CPAP did not affect transpulmonary driving pressure or effort per breath. HFNO and NIV reduced effort per minute (-95 cmHO*bpm [-140; -49] and -240 cmHO*bpm [-284; -196], respectively), whereas CPAP did not. NIV lowered effort per breath (-5.9 cmHO [-7.4; -4.4]) but increased driving pressure (3.4 cmH₂O [1.4; 5.4]). All strategies reduced respiratory rate, with HFNO producing the greatest decrease (HFNO: -5 breaths*min [-6; -4]; CPAP: -2 breaths*min [-4; -1]; NIV: -4 breaths*min [-5; -2]); all interventions improved PaO/FiO, with CPAP and NIV showing greater effects than HFNO (CPAP: 67 mmHg [55; 80]; NIV: 82 mmHg [56; 108]; HFNO: 24 mmHg [5; 43]). None of the strategies affected PaCO.

CONCLUSIONS: Noninvasive strategies exert distinct physiological effects: HFNO and NIV reduce effort per minute, while only NIV decreases effort per breath but at the cost of increased driving pressure. CPAP has neutral effects on driving pressure and effort. CPAP and NIV provide greater improvements in oxygenation than HFNO. Individualized selection based on effort levels may help balance the benefits and risks of noninvasive support.

PROSPERO REGISTRATION: CRD42024564035.

**中文摘要译文：**
背景：在低氧血症患者中，无创呼吸支持策略对肺损伤决定因素的各自影响仍不清楚，主要由于难以在同一研究中获得所有干预措施的标准化测量。我们进行了系统评价和网状Meta分析，以评估无创策略对急性低氧性呼吸衰竭患者跨肺驱动压和吸气努力的影响。

方法：我们进行了系统检索（Ovid MEDLINE、Embase、Scopus和PubMed），并对截至2025年2月16日发表的涉及低氧血症成人的生理学研究进行了网状Meta分析。我们纳入了在至少两种无创呼吸支持策略[标准氧疗、经鼻高流量氧疗（HFNO）、无创通气（NIV）和持续气道正压通气（CPAP）]下通过食管测压评估吸气努力的研究。结局指标包括跨肺驱动压、每次呼吸和每分钟的吸气努力、呼吸频率和气体交换。治疗效应以均数差[95%置信区间]表示。

结果：在5876篇文献中，纳入了13项研究（n=312例患者）（平均PaO/FiO=131（±48）mmHg，平均呼吸频率=28（±8）次/分钟）。与标准氧疗相比，HFNO和CPAP不影响跨肺驱动压或每次呼吸的努力。HFNO和NIV降低了每分钟的努力（分别为-95 cmH₂O*bpm [-140; -49]和-240 cmH₂O*bpm [-284; -196]），而CPAP则没有。NIV降低了每次呼吸的努力（-5.9 cmH₂O [-7.4; -4.4]）但增加了驱动压（3.4 cmH₂O [1.4; 5.4]）。所有策略均降低了呼吸频率，其中HFNO产生的降幅最大（HFNO：-5次/分钟[-6; -4]；CPAP：-2次/分钟[-4; -1]；NIV：-4次/分钟[-5; -2]）；所有干预措施均改善了PaO/FiO，其中CPAP和NIV的效果优于HFNO（CPAP：67 mmHg [55; 80]；NIV：82 mmHg [56; 108]；HFNO：24 mmHg [5; 43]）。所有策略均不影响PaCO₂。

结论：无创策略产生不同的生理效应：HFNO和NIV降低每分钟的努力，而只有NIV降低每次呼吸的努力，但代价是增加驱动压。CPAP对驱动压和努力具有中性效应。CPAP和NIV在改善氧合方面优于HFNO。基于努力水平的个体化选择可能有助于平衡无创支持的获益与风险。

PROSPERO注册号：CRD42024564035。

### 第二部分 AI 大师评价

本研究通过网状Meta分析系统评估了四种无创呼吸支持策略在急性低氧性呼吸衰竭中的生理效应，具有重要的临床指导价值。研究创新性地采用食管测压技术量化吸气努力，首次清晰揭示了不同策略对跨肺驱动压和呼吸努力的差异化影响。关键发现表明NIV虽然能有效降低呼吸努力，但会增加驱动压，存在潜在的肺损伤风险；而HFNO在降低呼吸频率方面效果最佳。该研究为临床个体化选择呼吸支持策略提供了精准的生理学依据，但样本量相对有限且主要关注生理参数，未来需要更多临床结局研究来验证这些发现的实际临床意义。

---

## 11. 躯干倾斜对肥胖与非肥胖ARDS机械通气患者呼吸效应的影响

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41152895](https://pubmed.ncbi.nlm.nih.gov/41152895)
**期刊：** Critical care (London, England)
**PMID：** 41152895
**DOI：** 10.1186/s13054-025-05694-z

### 第一部分 原文与翻译

**英文原标题：** Respiratory effects of trunk inclination in obese and non-obese patients mechanically ventilated for ARDS.

**英文摘要原文：**
BACKGROUND: Adjusting trunk inclination in patients with acute respiratory distress syndrome directly affects physiological variables such as respiratory mechanics and PaCO levels. These effects may vary according to the body mass index (BMI) due to differences in lung and chest wall mechanics, highlighting the need for further investigation to clarify the clinical relevance of body position across patient subgroups.

METHODS: A secondary analysis compared the physiological effects of increasing trunk inclination angles between mechanically ventilated patients with obesity (BMI≥30 kg/m) and those without obesity (BMI<30 kg/m).

RESULTS: Data from 159 patients collected across seven individual studies were analyzed. The following physiological changes were observed in response to increased trunk inclination: Sixty-five patients with obesity presented a greater decrease in respiratory system compliance (-7.5 [-10; -5] mL/cmHO; p<0.001) compared to ninety-four patients without obesity (-3.5 [-7; -0.08] mL/cmHO; p=0.045). Lung compliance decreased in obese patients (-7.8 [-12.4; -3.3] mL/cmHO; p<0.001), whereas no significant changes were observed in patients without obesity (-5.9 [-14.2; 2.3] mL/cmHO; p=0.160). Chest wall compliance decreased by -42.9 [-63.2; -22.6] mL/cmHO (p<0.001) in obese patients and by -47.7 [-95.3; -0.15] mL/cmHO in non-obese patients (p=0.049). PaCO increased in obese patients by 4.6 [1.4; 7.8] mmHg (p=0.004) but not in patients without obesity (2.5 [-0.6; 5.6] (p=0.113). No significant differences were observed in PaO/FO between phases.

CONCLUSIONS: Increasing the trunk inclination angle during passive ventilation reduces respiratory system, lung, and chest wall compliance. This effect was more pronounced in obese patients. Moreover, only this population exhibited an increase in PaCO. We acknowledge the methodological heterogeneity across the included studies, which may have influenced the results. Overall, our results highlight the importance of considering BMI as a significant variable that influences individual physiological responses to changes in bed inclination.

**中文摘要译文：**
背景：调整急性呼吸窘迫综合征患者的躯干倾斜角度直接影响生理变量，如呼吸力学和PaCO水平。由于肺和胸壁力学的差异，这些效应可能根据体重指数（BMI）而变化，这凸显了需要进一步研究以阐明体位在不同患者亚组中的临床相关性。

方法：一项二次分析比较了增加躯干倾斜角度对肥胖（BMI≥30 kg/m²）和非肥胖（BMI<30 kg/m²）机械通气患者生理效应的影响。

结果：分析了来自七项独立研究收集的159名患者数据。观察到以下对增加躯干倾斜的生理变化：65名肥胖患者表现出比94名非肥胖患者更大的呼吸系统顺应性下降（-7.5 [-10; -5] mL/cmH₂O；p<0.001 vs -3.5 [-7; -0.08] mL/cmH₂O；p=0.045）。肥胖患者肺顺应性下降（-7.8 [-12.4; -3.3] mL/cmH₂O；p<0.001），而非肥胖患者未观察到显著变化（-5.9 [-14.2; 2.3] mL/cmH₂O；p=0.160）。肥胖患者胸壁顺应性下降-42.9 [-63.2; -22.6] mL/cmH₂O（p<0.001），非肥胖患者下降-47.7 [-95.3; -0.15] mL/cmH₂O（p=0.049）。肥胖患者PaCO增加4.6 [1.4; 7.8] mmHg（p=0.004），但非肥胖患者未增加（2.5 [-0.6; 5.6] mmHg；p=0.113）。各阶段间PaO/FO未观察到显著差异。

结论：被动通气期间增加躯干倾斜角度会降低呼吸系统、肺和胸壁的顺应性。这种效应在肥胖患者中更为明显。此外，只有该人群表现出PaCO增加。我们承认纳入研究的方法学异质性可能影响了结果。总体而言，我们的结果强调了将BMI视为影响个体对床位倾斜变化生理反应的重要变量的重要性。

### 第二部分 AI 大师评价

本研究通过二次分析探讨了躯干倾斜角度对肥胖与非肥胖ARDS机械通气患者呼吸生理的影响。研究创新性地揭示了BMI在体位调节效应中的关键作用，发现肥胖患者对躯干倾斜表现出更显著的呼吸系统顺应性下降和PaCO升高。这一发现具有重要临床价值，为ARDS患者的个体化体位管理提供了循证依据，强调了在呼吸支持策略中考虑患者BMI的必要性。虽然研究存在方法学异质性的局限性，但其结果对优化危重症患者呼吸治疗具有重要指导意义。

---

## 12. 建立人腺病毒55型诱导呼吸道疾病的食蟹猴模型

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41151607](https://pubmed.ncbi.nlm.nih.gov/41151607)
**期刊：** The Journal of infectious diseases
**PMID：** 41151607
**DOI：** 10.1093/infdis/jiaf542

### 第一部分 原文与翻译

**英文原标题：** Establishment of a Cynomolgus Macaque Model for Human Adenovirus Type 55-Induced Respiratory Disease.

**英文摘要原文：**
BACKGROUND: Human adenovirus type 55 (HAdV-55) is an emerging respiratory pathogen associated with severe pneumonia outbreaks, particularly in military populations and community settings. The lack of a suitable nonhuman primate model has limited the study of viral pathogenesis and the evaluation of vaccines and therapeutics.

METHODS: Cynomolgus macaques were first administered PBS intranasally and intratracheally as a negative control and allowed to recover for 20 days. The same animals were subsequently infected intranasally and intratracheally with HAdV-55. Clinical signs, hematologic parameters, cytokine responses, imaging, histopathology, and immunologic profiles were monitored over time.

RESULTS: Infected macaques exhibited respiratory symptoms including nasal discharge, cough, weight loss, and increased respiratory and heart rates. Lung imaging revealed peri-bronchial consolidation and ground-glass opacities. Histopathology showed granulomatous inflammation and macrophage infiltration, resembling human disease. Hematological analysis demonstrated phase-specific immune responses: early neutrophilia and basophilia, followed by eosinophilia and increased large unstained cells. Cytokine profiling showed early induction of IFN-γ, IFN-β, and IL-6, with delayed IL-8 elevation and IL-4 suppression. Virus-specific antibodies were detectable by day 7, and neutralizing antibodies by day 3 post-infection. However, IFN-γ-producing T-cell responses remained undetectable up to day 14.

CONCLUSIONS: This study establishes a cynomolgus macaque model that recapitulates key clinical and immunological features of HAdV-55-induced respiratory disease in humans. The model provides a robust platform for advancing our understanding of HAdV-55 pathogenesis and for the preclinical evaluation of candidate vaccines and therapeutics.

**中文摘要译文：**
背景：人腺病毒55型（HAdV-55）是一种新兴的呼吸道病原体，与严重的肺炎暴发相关，特别是在军事人群和社区环境中。缺乏合适的非人灵长类动物模型限制了病毒发病机制的研究以及疫苗和治疗药物的评估。

方法：首先将食蟹猴经鼻内和气管内给予PBS作为阴性对照，并允许其恢复20天。随后，同一动物经鼻内和气管内感染HAdV-55。随时间监测临床症状、血液学参数、细胞因子反应、影像学、组织病理学和免疫学特征。

结果：感染的食蟹猴表现出呼吸道症状，包括鼻分泌物、咳嗽、体重减轻以及呼吸频率和心率增加。肺部影像显示支气管周围实变和磨玻璃样阴影。组织病理学显示肉芽肿性炎症和巨噬细胞浸润，类似于人类疾病。血液学分析显示阶段特异性免疫反应：早期中性粒细胞增多和嗜碱性粒细胞增多，随后嗜酸性粒细胞增多和大未染色细胞增加。细胞因子谱分析显示IFN-γ、IFN-β和IL-6早期诱导，IL-8延迟升高和IL-4抑制。病毒感染后第7天可检测到病毒特异性抗体，第3天可检测到中和抗体。然而，直到第14天，产生IFN-γ的T细胞反应仍无法检测到。

结论：本研究建立了一个食蟹猴模型，重现了HAdV-55诱导的人类呼吸道疾病的关键临床和免疫学特征。该模型为推进我们对HAdV-55发病机制的理解以及候选疫苗和治疗药物的临床前评估提供了一个强大的平台。

### 第二部分 AI 大师评价

本研究成功建立了首个食蟹猴模型用于人腺病毒55型（HAdV-55）呼吸道疾病研究，填补了该领域动物模型的空白。研究采用鼻内和气管内联合感染的方式，通过多维度监测手段系统评估了病毒感染后的临床表现、免疫反应和病理变化。关键发现包括模型成功模拟了人类疾病的典型特征，如呼吸道症状、肺部影像学改变和特异性免疫反应模式。该模型的建立具有重要的创新性和临床价值，为HAdV-55的发病机制研究、疫苗和治疗药物开发提供了可靠的临床前评价平台，但研究也提示T细胞免疫反应可能相对延迟，这为后续研究提供了重要方向。

---

## 13. 免疫抑制脓毒症患者炎症亚表型的预后相关性研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41150892](https://pubmed.ncbi.nlm.nih.gov/41150892)
**期刊：** Critical care medicine
**PMID：** 41150892
**DOI：** 10.1097/CCM.0000000000006920

### 第一部分 原文与翻译

**英文原标题：** Prognostic Relevance of Inflammatory Subphenotypes in Immunocompromised Patients With Sepsis.

**英文摘要原文：**
OBJECTIVES: Hyperinflammatory and hypoinflammatory molecular subphenotypes in sepsis and acute respiratory distress syndrome have divergent mortality and treatment responses in secondary analyses of randomized controlled trials. However, the prevalence of immunocompromise is low in these populations, and how preexisting immunocompromise contributes to subphenotypes is unknown. We studied two observational sepsis cohorts to test associations between immunocompromise and the hyperinflammatory subphenotype and to assess whether the prognostic relevance of molecular subphenotypes is generalizable to immunocompromised populations.

DESIGN: Observational cohort study.

SETTING: Prospective data from two ICU cohorts in the United States.

PATIENTS: We included 1826 patients from two combined sepsis cohorts.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: We defined immunocompromise as a history of solid organ transplant, AIDS, hematologic malignancy, solid malignancy on chemotherapy, or immunosuppressive medication use. Subphenotype was previously assigned using latent class analysis. We used logistic regression to investigate associations between type of immunocompromise and hyperinflammatory subphenotype. Models were repeated with individual covariates known or hypothesized to be associated with the hyperinflammatory subphenotype. Kaplan-Meier survival plots were used to assess mortality differences by subphenotype. Hematologic malignancy was strongly associated with the hyperinflammatory subphenotype (odds ratio [OR], 4.3; p < 0.0001), an association that persisted after adjustment for identified pathogen, presence of bacteremia, or illness severity. History of solid organ transplantation was also associated with the hyperinflammatory subphenotype (OR, 1.6; p = 0.02) but was no longer significant after accounting for bacteremia. Hyperinflammatory classification was associated with a decreased likelihood of survival in hematologic malignancy, but not in organ transplant or solid malignancy populations.

CONCLUSIONS: Preexisting immune status is associated with subphenotype assignment and may influence its prognostic utility.

**中文摘要译文：**
目的：在随机对照试验的二次分析中，脓毒症和急性呼吸窘迫综合征中的高炎症和低炎症分子亚表型显示出不同的死亡率和治疗反应。然而，这些人群中免疫抑制的患病率较低，且预先存在的免疫抑制如何影响亚表型尚不清楚。我们研究了两个观察性脓毒症队列，以检验免疫抑制与高炎症亚表型之间的关联，并评估分子亚表型的预后相关性是否可推广至免疫抑制人群。

设计：观察性队列研究。

设置：来自美国两个ICU队列的前瞻性数据。

患者：我们纳入了来自两个合并脓毒症队列的1826名患者。

干预措施：无。

测量与主要结果：我们将免疫抑制定义为有实体器官移植史、艾滋病、血液系统恶性肿瘤、接受化疗的实体恶性肿瘤或使用免疫抑制药物的病史。亚表型先前已使用潜在类别分析进行分配。我们使用逻辑回归来研究免疫抑制类型与高炎症亚表型之间的关联。模型重复使用了已知或假设与高炎症亚表型相关的单个协变量。使用Kaplan-Meier生存图评估不同亚表型的死亡率差异。血液系统恶性肿瘤与高炎症亚表型密切相关（比值比[OR]为4.3；p < 0.0001），这种关联在调整了已识别病原体、菌血症存在或疾病严重程度后仍然存在。实体器官移植史也与高炎症亚表型相关（OR为1.6；p = 0.02），但在考虑菌血症后不再显著。高炎症分类与血液系统恶性肿瘤患者生存可能性降低相关，但在器官移植或实体恶性肿瘤人群中未观察到这种关联。

结论：预先存在的免疫状态与亚表型分配相关，并可能影响其预后效用。

### 第二部分 AI 大师评价

本研究通过观察性队列设计，深入探讨了免疫抑制状态对脓毒症炎症亚表型分布及预后意义的影响。研究创新性地发现血液系统恶性肿瘤患者强烈倾向于高炎症亚表型，且这种关联独立于病原体类型和疾病严重程度，而实体器官移植与高炎症亚表型的关联则受菌血症因素影响。该研究填补了脓毒症分子分型在特殊免疫状态人群中应用价值的空白，为精准医学在危重症领域的实践提供了重要依据。然而，研究作为观察性设计，无法确立因果关系，且样本量相对有限，未来需要更大规模的前瞻性研究验证这些发现，并探索针对不同免疫状态患者的个体化治疗策略。

---

速递结束，祝您工作愉快！